Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -45

Should You Pick Boston Scientific Stock Over Its Competitors?

Guidance lowered Operational disruption AI-generated analysis

πŸ“‰ BSX stock dropped 56.8% year-to-date as of November 3, 2026, trading at the lowest P/E multiple among six major healthcare peers despite ranking third in revenue growth and operating margins.

πŸ“Š Revenue growth slowed sequentially across all quarters in fiscal 2026, decelerating from 15.9% in Q4 to just 1.4% in Q3 due to a cyber incident and competitive pressures.

πŸ’» A cyber incident caused an eight-day production halt, contributing to a revised full-year 2026 revenue growth guidance of 4.3%, down from the previous 6.0% estimate.

πŸ“‰ Sales in the EP business fell 5% in Q3 and are expected to continue losing market share until a new product launches in early 2028.

πŸ₯ WATCHMAN sales declined 7% in the U.S., adding pressure to overall revenue as management expects these two segments to drag down performance in 2027.

πŸ“… Management forecasts a trough in 2027 with declining fourth-quarter revenue of 1% to 3%, anticipating a return to high performance only in 2028.

πŸ” Investors are focused on the February 2027 earnings report for critical updates on EP and WATCHMAN segment recovery and new product launch timelines.

Bullish Signals
  • Boston Scientific ranks third among six healthcare peers for both revenue growth and operating margin over the latest four quarters, demonstrating resilient core business performance.
  • The company's interventional cardiology business is growing consistently at 19%, offsetting some of the drag from its struggling EP and WATCHMAN segments.
  • Management expects to return to high performance in 2028 following a projected trough, suggesting potential for significant stock re-rating if product launches succeed.
Risk Factors
  • Revenue growth has slowed in every quarter of fiscal 2026, dropping from 15.9% in Q4 to just 1.4% in Q3 due to a cyber incident and competitive erosion.
  • Management expects fourth-quarter revenue to fall 1% to 3% as customers work through inventory built up after the recent cyber incident.
  • Sales in the EP business fell 5% in Q3, with management warning that market share will continue to erode until a new product launches in early 2028.
  • WATCHMAN sales declined 7% in the U.S., contributing to overall revenue pressure and lowering the company's multiple relative to rivals.
  • Management projects 2027 as a trough period where sales and adjusted earnings per share will be challenged, delaying recovery until 2028.
Full Analysis
Boston Scientific (BSX) stock has underperformed its healthcare peer group, dropping 56.8% year-to-date as of November 3, 2026, and trading at the lowest price-to-earnings multiple among six major rivals. Despite this valuation discount, the company ranks third in revenue growth and operating margins over the last four quarters, reporting an 8.9% revenue increase compared to Stryker's 7.9% and Medtronic's 9.8%. However, the market appears to price in significant headwinds regarding specific product lines that are currently struggling with market share erosion. Underlying the stock's weakness is a distinct slowdown in sales growth across all quarters of fiscal year 2026, which decelerated from 15.9% in Q4 2025 to just 1.4% in Q3 2026. Management attributes this sharp decline primarily to a cyber incident that halted production and shipping for eight days, as well as competitive pressures in its EP and WATCHMAN businesses. Consequently, the company has revised its full-year 2026 revenue growth guidance down to 4.3% from an earlier estimate of 6.0%, signaling that current performance is insufficient to offset losses in key segments. Looking ahead, Boston Scientific expects fourth-quarter revenue to decline by 1% to 3% as customers work through inventory built up during the recent cyber incident. Management warns that 2027 will be a trough period where sales and adjusted earnings per share face challenges, with some major product platforms slipping by six months in development. The company anticipates a return to high performance only in 2028, contingent on the launch of new products in early 2028 and meaningful improvement in its EP segment, which is expected to lose market share until that time. Investors are closely watching the February 2027 earnings report for signs of recovery in the EP and WATCHMAN segments, which currently account for significant pressure on overall sales. While the rest of the company, including interventional cardiology, continues to grow at a healthy 19% rate, management indicates that this growth will not be enough to offset the drag from these two specific businesses in 2027. The stock's low valuation reflects market skepticism about whether Boston Scientific can regain its competitive footing without a successful product launch or significant share recovery in its struggling divisions.